fda bpc-157 ineligible for compounding 503a 503b The peptide regulatory landscape in 2026 is in active flux. After the placed 19 popular peptides in Category 2 in late 2023, HHS Secretary RFK Jr. announced in February 2026 that 503B Compounding Master Guide –

Although the complex remains highly dynamic upon binding, we were able to obtain a set of distance restraints from these experiments

This mechanism is currently being compared to mitochondrial uncoupling agents in various bioenergetic studies

If you couldn't tolerate GHK-CU, retinoids might work well, though they have their own adjustment period

For clients who have both fat-loss goals and musculoskeletal issues (e.g., the users interest in mobility/gut recovery, serum therapies, peptides) this could be a conceivable fit though evidence is not robust yet

The honest caveat: GHK-Cu is not a miracle hair loss cure